Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 30, 2024 09:25 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million

Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...
March 23, 2023 08:05 ET | Source: Palisade Bio, Inc.

Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 ...
December 16, 2022 08:05 ET | Source: Palisade Bio, Inc.

Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

Topline data readout from study expected in first half of 2023 Carlsbad, CA, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company...
December 07, 2022 08:35 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million

Proceeds extend cash runway to fund operations into early 2024 Carlsbad, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company...
September 23, 2022 16:30 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...